{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T06:43:27.051908+00:00","company":{"ticker":"AYTU","cik":1385818,"company_name":"AYTU BIOPHARMA, INC"},"pagination":{"limit":100,"returned":6,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"33a1bf6635df3cc3a84a118248bf39690c536109","cik":1385818,"ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","filed_at":"2026-04-02T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amended 2023 Prefunded Warrant","agreement_type":"other","counterparty":"certain institutional investors","effective_date":"2026-03-31","item_codes_triggered":["1.01"],"value_text":null},"claim":"AYTU BIOPHARMA, INC amended Amended 2023 Prefunded Warrant with certain institutional investors (effective 2026-03-31).","evidence_excerpt":"the Company and the Investors, as applicable, entered into (i) an Amended and Restated June 2023 Prefunded Warrant (\"Amended 2023 Prefunded Warrant\"), (ii) an Amended and Restated June 2023 Tranche A Warrant (\"Amended 2023 Tranche A Warrant\") and (iii) an Amended and Restated June 2025 Prefunded Warrant (\"Amended 2025 Prefunded Warrant\"), pursuant to which the Company canceled the previously issued Warrants and issued to the Investors, as applicable, an Amended 2023 Prefunded Warrant, an Amended 2023 Tranche A Warrant and an Amended 2025 Prefunded Warrant, with revised Blockers","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-26-011116","anchor_url":"https://secwatch.observer/filing/0001437749-26-011116#claim-33a1bf6635df3cc3a84a118248bf39690c536109","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926011116/0001437749-26-011116-index.htm"},{"fact_type":"debt_financing","fact_key":"0e45690818becbe392b48db2f2a04ad8feaf4ba5","cik":1385818,"ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-06-23T23:59:59+00:00","payload":{"counterparty":"Eclipse Business Capital LLC","effective_date":"2025-06-20","event":"amendment","instrument_type":"revolving_credit","interest_rate_text":"SOFR plus 5.50%","item_codes_triggered":["2.03"],"maturity_text":"June 12, 2029","principal_text":"$1.5 million incremental advance"},"claim":"AYTU BIOPHARMA, INC amended revolving credit of $1.5 million incremental advance with Eclipse Business Capital LLC at SOFR plus 5.50% maturing June 12, 2029.","evidence_excerpt":"extended the revolving credit facility (the “Eclipse Revolving Loan”) maturity date to June 12, 2029, and increased the potential maximum borrowing base pursuant to a $1.5 million incremental advance (the “Eclipse Incremental Advance”), at an interest rate of the SOFR plus 5.50%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-020973","anchor_url":"https://secwatch.observer/filing/0001437749-25-020973#claim-0e45690818becbe392b48db2f2a04ad8feaf4ba5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm"},{"fact_type":"debt_financing","fact_key":"b1c33db405e55645912b976e07dc65aa69a9b876","cik":1385818,"ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","filed_at":"2025-06-23T23:59:59+00:00","payload":{"counterparty":"Eclipse Business Capital LLC","effective_date":"2025-06-20","event":"amendment","instrument_type":"term_loan","interest_rate_text":null,"item_codes_triggered":["2.03"],"maturity_text":"June 12, 2029","principal_text":"outstanding principal amount of $13.0 million"},"claim":"AYTU BIOPHARMA, INC amended term loan of outstanding principal amount of $13.0 million with Eclipse Business Capital LLC maturing June 12, 2029.","evidence_excerpt":"extended the term loan (the “Eclipse Term Loan”) maturity date to June 12, 2029, and increased the Eclipse Term Loan resulting in an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001437749-25-020973","anchor_url":"https://secwatch.observer/filing/0001437749-25-020973#claim-b1c33db405e55645912b976e07dc65aa69a9b876","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm"},{"fact_type":"executive_change","fact_key":"08781d05b7","cik":1385818,"ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-11-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-11","interim":false,"role":"Chief Financial Officer, Corporate Secretary and Treasurer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Ryan Selhorn was appointed as Chief Financial Officer, Corporate Secretary and Treasurer at AYTU BIOPHARMA, INC.","evidence_excerpt":"On November 11, 2024, the board of directors of the Company (the \" Board \") appointed Ryan Selhorn as Chief Financial Officer, Corporate Secretary and Treasurer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-034898","anchor_url":"https://secwatch.observer/filing/0001437749-24-034898#claim-08781d05b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm"},{"fact_type":"executive_change","fact_key":"b52154d0ce","cik":1385818,"ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-11-13T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-11-11","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Ryan Selhorn","successor_named":true},"claim":"Mark K. Oki was terminated as Chief Financial Officer at AYTU BIOPHARMA, INC.","evidence_excerpt":"On November 11, 2024, Mark K. Oki was terminated as Chief Financial Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-034898","anchor_url":"https://secwatch.observer/filing/0001437749-24-034898#claim-b52154d0ce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924034898/0001437749-24-034898-index.htm"},{"fact_type":"earnings_release","fact_key":"f2f7833d61d27d94c74bc114df161d136f6ca9b6","cik":1385818,"ticker":"AYTU","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$0.52 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$2.9 million","period_text":"fiscal 2024 third quarter","report_date":"2024-05-15","result_type":"reported_results","revenue_text":"$18.0 million"},"claim":"AYTU BIOPHARMA, INC reported fiscal 2024 third quarter results: revenue $18.0 million, net income $2.9 million, EPS $0.52 per share.","evidence_excerpt":"on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. ​ Q3 2024 Highlights ● Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment. ● ADHD Portfolio (Adzenys XR-ODT® and","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001437749-24-017058","anchor_url":"https://secwatch.observer/filing/0001437749-24-017058#claim-f2f7833d61d27d94c74bc114df161d136f6ca9b6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/0001437749-24-017058-index.htm"}]}